Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET

Nuclear Medicine and Biology

Volumn 37, Issue 3, 2010, Pages 289-297

  Tinianow, Jeff N ^a   Gill, Herman S ^a   Ogasawara, Annie ^a   Flores, Judith E ^a   Vanderbilt, Alexander N ^a   Luis, Elizabeth ^a   Vandlen, Richard ^a   Darwish, Martine ^a   Junutula, Jagath R ^a   Williams, Simon P ^a   Marik, Jan ^a  

^a GENENTECH INC   (United States)

Author keywords

Bromoacetate; Imaging; ImmunoPET; Iodoacetate; Maleimide; PHESELECTOR; Site specifically labeled antibodies; Thiol specific desferrioxamine reagent; THIOMAB; Trastuzumab; Zirconium 89

Indexed keywords

DEFEROXAMINE; DEFEROXAMINE MESYLATE; DESFERRIOXAMINE THIO TRASTUZUMAB ZR 89 CONJUGATE; IODOACETIC ACID; MONOCLONAL ANTIBODY; N [4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYL]DESFERRIOXAMINE; N BROMOACETYLDESFERRIOXAMINE; N HYDROXYSUCCINILIDYL 4 [N MALEIMIDOMETHYL]CYCLOHEXANE 1 CARBOXYLIC ACID; N HYDROXYSUCCINIMIDYL IODOACETATE; N IODOACETYLDESFERRIOXAMINE; REAGENT; SUCCINIMIDE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89; DIAGNOSTIC AGENT; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ACYLATION; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CHELATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG PURITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PH; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; EVALUATION; FEMALE; HUMAN; IMMUNOLOGY; METABOLIC CLEARANCE RATE; METHODOLOGY; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOASSAY; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNODETECTION; RADIOISOTOPES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; ZIRCONIUM;

EID: 77950296003     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.11.010     Document Type: Article

References (44)

1. van Dongen G.A., Visser G.W., Lub-de Hooge M.N., de Vries E.G., Perk L.R. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 2007, 12:1379-1389.
2. Verel I., Visser G.W., van Dongen G.A. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005, 46(Suppl 1):164S-171S.
3. Larson S.M., Pentlow K.S., Volkow N.D., Wolf A.P., Finn R.D., Lambrecht R.M., et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 1992, 33:2020-2023.
4. 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging 2004, 31:1645-1652.
5. Lee F.T., Hall C., Rigopoulos A., Zweit J., Pathmaraj K., O'Keefe G.J., et al. Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med 2001, 42:764-769.
6. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003, 44:1962-1969.
7. Jain M., Batra S.K. Genetically engineered antibody fragments and PET imaging: a new era of radioimmunodiagnosis. J Nucl Med 2003, 44:1970-1972.
8. 124I activity distributions using a clinical PET/CT scanner. J Nucl Med 2004, 45:1237-1244.
9. Robinson M.K., Doss M., Shaller C., Narayanan D., Marks J.D., Adler L.P., et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005, 65:1471-1478.
10. Jayson G.C., Zweit J., Jackson A., Mulatero C., Julyan P., Ranson M., et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002, 94:1484-1493.
11. Divgi C.R., Pandit-Taskar N., Jungbluth A.A., Reuter V.E., Gonen M., Ruan S., et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007, 8:304-310.
12. Geissler F., Anderson S.K., Press O. Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells. Cellular immunology 1991, 137:96-110.
13. Shih L.B., Thorpe S.R., Griffiths G.L., Diril H., Ong G.L., Hansen H.J., et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 1994, 35:899-908.
14. Perera R.M., Zoncu R., Johns T.G., Pypaert M., Lee F.T., Mellman I., et al. Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. Neoplasia (New York, N.Y) 2007, 9:1099-1110.
15. Meijs W.E., Haisma H.J., Klok R.P., van Gog F.B., Kievit E., Pinedo H.M., et al. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J Nucl Med 1997, 38:112-118.
16. Meijs W.E., Haisma H.J., Van der Schors R., Wijbrandts R., Van den Oever K., Klok R.P., et al. A facile method for the labeling of proteins with zirconium isotopes. Nucl Med Biol 1996, 23:439-448.
17. 89Zr-labeled monoclonal antibodies. J Nucl Med 2003, 44:1271-1281.
18. Perk L.R., Vosjan M.J., Visser G.W., Budde M., Jurek P., Kiefer G.E., et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging 2009.
19. Verel I., Visser G.W., Boerman O.C., van Eerd J.E., Finn R., Boellaard R., et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm 2003, 18:655-661.
20. Nagengast W.B., de Vries E.G., Hospers G.A., Mulder N.H., de Jong J.R., Hollema H., et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007, 48:1313-1319.
21. 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005, 46:1898-1906.
22. 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2008, 35:1857-1867.
23. 90Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging 2006, 33:1337-1345.
24. Borjesson P.K., Jauw Y.W., Boellaard R., de Bree R., Comans E.F., Roos J.C., et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 2006, 12:2133-2140.
25. 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009, 50:123-131.
26. 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging. J Nucl Med 2009.
27. Wang L., Amphlett G., Blattler W.A., Lambert J.M., Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005, 14:2436-2446.
28. Hamblett K.J., Senter P.D., Chace D.F., Sun M.M., Lenox J., Cerveny C.G., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004, 10:7063-7070.
29. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med 2007, 48:304-310.
30. 18F labeling for immuno-PET: where speed and contrast meet. J Nucl Med 2007, 48:170-172.
31. Tait J.F., Smith C., Levashova Z., Patel B., Blankenberg F.G., Vanderheyden J.L. Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods. J Nucl Med 2006, 47:1546-1553.
32. Schellenberger E.A., Bogdanov A., Petrovsky A., Ntziachristos V., Weissleder R., Josephson L. Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy. Neoplasia (New York, N.Y) 2003, 5:187-192.
33. 111In labelled antibodies give low liver backgrounds and improved radioimmunoscintigraphy. Int J Radiat Appl Instrum 1986, 13:347-352.
34. Rodwell J.D., Alvarez V.L., Lee C., Lopes A.D., Goers J.W., King H.D., et al. Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc Natl Acad Sci U S A 1986, 83:2632-2636.
35. Lyons A., King D.J., Owens R.J., Yarranton G.T., Millican A., Whittle N.R., et al. Site-specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Eng 1990, 3:703-708.
36. Leung S., Losman M.J., Govindan S.V., Griffiths G.L., Goldenberg D.M., Hansen H.J. Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments. J Immunol 1995, 154:5919-5926.
37. Junutula J.R., Bhakta S., Raab H., Ervin K.E., Eigenbrot C., Vandlen R., et al. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods 2008, 332:41-52.
38. Junutula J.R., Raab H., Clark S., Bhakta S., Leipold D.D., Weir S., et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008, 26:925-932.
39. Holland J.P., Sheh Y., Lewis J.S. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol 2009, 36:729-739.
40. Munson P.J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980, 107:220-239.
41. Mealey J. Turn-over of carrier-free zirconium-89 in man. Nature 1957, 179:673-674.
42. Fletcher C.R. The radiological hazards of zirconium-95 and niobium-95. Health Phys 1969, 16:209-220.
43. 95Nb in newborn, juvenile and adult rats. Health Phys 1972, 22:373-378.
44. 18F exemplified by quantitative positron emission tomography of human epidermal growth factor receptor 2. J Med Chem 2009, 52:5816-5825.